Eventide Asset Management LLC Has $86.88 Million Stake in Collegium Pharmaceutical, Inc. $COLL

Eventide Asset Management LLC decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 21.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,876,239 shares of the specialty pharmaceutical company’s stock after selling 514,673 shares during the quarter. Collegium Pharmaceutical makes up about 1.4% of Eventide Asset Management LLC’s investment portfolio, making the stock its 15th largest position. Eventide Asset Management LLC owned 5.94% of Collegium Pharmaceutical worth $86,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the stock. Barclays PLC boosted its stake in Collegium Pharmaceutical by 40.0% in the 4th quarter. Barclays PLC now owns 103,609 shares of the specialty pharmaceutical company’s stock valued at $4,797,000 after buying an additional 29,578 shares in the last quarter. Aigen Investment Management LP acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at $329,000. Marshall Wace LLP boosted its stake in Collegium Pharmaceutical by 76.5% in the 4th quarter. Marshall Wace LLP now owns 492,360 shares of the specialty pharmaceutical company’s stock valued at $22,796,000 after buying an additional 213,347 shares in the last quarter. Johnson Investment Counsel Inc. acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at $239,000. Finally, Public Sector Pension Investment Board boosted its stake in Collegium Pharmaceutical by 19.3% in the 4th quarter. Public Sector Pension Investment Board now owns 146,669 shares of the specialty pharmaceutical company’s stock valued at $6,791,000 after buying an additional 23,770 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $34.64 on Friday. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The firm has a market cap of $1.12 billion, a P/E ratio of 16.98 and a beta of 0.74. The business’s fifty day moving average is $33.99 and its two-hundred day moving average is $40.53. Collegium Pharmaceutical, Inc. has a 52 week low of $29.08 and a 52 week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.49 earnings per share. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

COLL has been the topic of several recent analyst reports. Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.